This message contains images. If you don't see images, click here to view.
Advertise in this news brief.




Text Version   RSS   Subscribe   Unsubscribe   Archive   Media Kit July 02, 2015


 

Advertisement

ASCO endorses ASTRO guideline on radiation therapy after surgery for endometrial cancer
American Society of Clinical Oncology
The American Society of Clinical Oncology recently issued an endorsement of the American Society for Radiation Oncology clinical practice guideline on postoperative radiation therapy for women with endometrial (uterine) cancer. The endorsement outlines treatments that ASTRO and ASCO agree should be the standard of care for women with endometrial cancer, based on the best available evidence. It also underscores areas where more research is needed to determine how women should be treated.
   Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE  


Advertisement


Findings suggest improvement in management of localized prostate cancer
The JAMA Network Journals via Medical Xpress
After years of over treatment for patients with low-risk prostate cancer, rates of active surveillance/ watchful waiting increased sharply in 2010 through 2013, and high-risk disease was more often treated appropriately with potentially curative local treatment rather than androgen deprivation alone, according to a study in the July 7 issue of JAMA.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


Why it is important to predict which lymphoma patients may relapse early
Medical News Today
After analyzing data on hundreds of cases, researchers suggest that two years — rather than the more common five years for many cancer patients — might be a more practical survival goal for patients with a type of non-Hodgkin lymphoma called follicular lymphoma.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE
Looking for similar articles? Search here, keyword LYMPHOMA.


Advertisement
SPONSORED CONTENT


Register now for Accreditation 101: Learning the Basics of CoC Accreditation and Standards
ACS
The Commission on Cancer (CoC), a Quality Program of the American College of Surgeons, encourages you to attend Accreditation 101: Learning the Basics of CoC Accreditation and Standards in Baltimore on Sept. 11. This program provides practical information on how to achieve compliance and discusses your role as a member of a patient-centered, multidisciplinary cancer care team. This is the only education program that is developed and taught by CoC surveyors and staff. Learn how to turn theory into reality and see how the CoC standards are a guide for the development of a high-quality program that treats patients with cancer. Register today.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


Missed an issue of The Brief? Click here to visit The Brief archive page.


Concurrent chemoradiotherapy should remain standard of care for locally advanced non-small cell lung cancer
Cancer Therapy Advisor
Concurrent chemoradiotherapy alone should remain the standard of care for the treatment of patients with locally advanced non-small cell lung cancer (NSCLC), a new study published online in the Journal of Clinical Oncology has shown. Researchers sought to assess the efficacy of consolidation chemotherapy with docetaxel plus cisplatin after concurrent chemoradiotherapy with the same agents in patients with locally advanced NSCLC.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


PRODUCT SHOWCASE
  ADVANTAGE OF FACILITY MEMBERSHIP

Members of NCBC have access to our Information Exchange, which is helpful to the breast center staff and physicians because it allows members to post questions to the membership asking for insight and expertise on a specific breast center related matter. Together we will learn and grow. Join NCBC now to be part of the exchange.
 


Drug combo shows promise against rare bone cancer
Medical News Today
Like other cancers, tumor cells in Ewing sarcoma — a rare bone cancer that primarily affects children and young adults — have to keep repairing their faulty DNA to survive. Now, a team of researchers shows two drugs that interfere with this process work together very effectively to kill the cancer cells in lab cultures and mice.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


The CoC and the NAPBC are going social
Connect with the CoC and the NAPBC on Twitter. The CoC Twitter account (COC_ACS) has been open for almost three months and has nearly 250 followers. The NAPBC Twitter account (NAPBC_ACS) opened almost a year ago and has more than 700 followers. Following the success of the NAPBC Twitter account, our newest social media endeavor is Facebook. Make sure you like the NAPBC Facebook page. If you have suggestions on ways to enhance our social media efforts, please contact Susan Rubin.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article


PRODUCT SHOWCASE
  insight2oncology™: Cancer Data at Your Fingertips
CHAMPS Oncology’s new web-based system transforms cancer data into actionable information for strategic planning, operational and financial decisions.
  • CHAMPS Seeks i2o™ Early Adopters
  • i2o™ Provides Answers to Cancer Service Lines’ Questions
  • Access 75+ Cancer Data Reports (Migration, Utilization & More)
 


Cancer drug 49 times more potent than Cisplatin
University of Warwick via Medical Xpress
Tests have shown that a new cancer drug, FY26, is 49 times more potent than the clinically used treatment Cisplatin. Based on a compound of the rare precious metal osmium and developed by researchers at the University of Warwick's Department of Chemistry and the Warwick Cancer Research Unit, FY26 is able to shut down a cancer cell by exploiting weaknesses inherent in its energy generation.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


New studies expand the BRCA equation in breast cancer
OncLive
Although BRCA1/2 mutations have been intensely studied in breast cancer for more than a decade, researchers are still seeking to determine which patient populations should be screened for abnormalities and how best to integrate that information into treatment protocols. Two abstracts presented at the 2015 ASCO Annual Meeting explored those questions. In one study, researchers found evidence to support mutation testing of women 45 years or younger who have been diagnosed with any type of breast cancer.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


SPONSORED CONTENT


Mammograms may not reduce breast cancer deaths
Fox News
Breast cancer screenings may not lead to fewer deaths but may lead to overdiagnosis, United States researchers suggest. In areas of the U.S. with high levels of screening, more tumors were diagnosed — but breast cancer death rates were no lower than in areas with fewer screenings, researchers report. "The mortality results that we observed are far from definitive," cautioned Charles Harding, the study's lead author from Seattle.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


TRENDING ARTICLES
Missed last week's issue? See which articles your colleagues read most.

    Hematology, oncology communities react to ACA decision (Healio)
Atomic force microscope advance leads to new breast cancer research (Phys.Org)
Multimodality treatment for metastatic lung cancer with surgery may improve survival (Oncology Nurse Advisor)
Scientists identify key to preventing metastatic breast cancer (Oncology Nurse Advisor)
Colon cancer: Taking a step back to move forward (Weizmann Institute of Science via Medical Xpress)

Don't be left behind. Click here to see what else you missed.
 
Advertisement

Advertisement



The Brief

Colby Horton, Vice President of Publishing, 469.420.2601
Download media kit

Ashley Whipple, Senior Content Editor, 469.420.2642
Contribute news

Disclaimer: The Brief is a digest of news selected for the Commission on Cancer (CoC) and the National Accreditation Program for Breast Centers (NAPBC), both quality programs of the American College of Surgeons, from thousands of sources by the editors of MultiBriefs, an independent organization that also manages and sells advertising. The CoC and NAPBC do not endorse any of the advertised products and services. Opinions expressed in the articles are those of the author and not of the American College of Surgeons, the CoC and the NAPBC.


Be sure to add us to your address book or safe sender list so our emails get to your inbox. Learn how.

This edition of The Brief was sent to ##Email##. To unsubscribe, click here. Did someone forward this edition to you? Subscribe here — it's free!

Recent issues

July 1, 2015
June 24, 2015
June 17, 2015
June 3, 2015






7701 Las Colinas Ridge, Ste. 800, Irving, TX 75063